Lamivudine/tenofovir
(Redirected from Cimduo)
![]() | |
Combination of | |
---|---|
Lamivudine | Nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
Clinical data | |
Trade names | Cimduo, Temixys |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618039 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).[1][3] It contains lamivudine and tenofovir disoproxil.[1] It is taken by mouth.[1]
Lamivudine/tenofovir was approved for medical use in the United States in February 2018.[1][4]
References
- ^ 1.0 1.1 1.2 1.3 1.4 "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Archived from the original on 15 February 2020. Retrieved 26 March 2020.
- ^ "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Archived from the original on 14 February 2022. Retrieved 13 February 2022.
- ^ Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.
- ^ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Archived from the original on 26 March 2020. Retrieved 26 March 2020.
Further reading
- "WHO Public Assessment Report: HA414 - Lamivudine/Tenofovir disoproxil fumarate - 300mg/300mg - Tablets - Mylan Laboratories Ltd - India". World Health Organization (WHO). Archived from the original on 26 March 2020.
Lua error in mw.title.lua at line 346: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').
Categories:
- Short description with empty Wikidata description
- All articles lacking reliable references
- Use dmy dates from September 2019
- Articles with invalid date parameter in template
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs that are a combination of chemicals
- Fixed dose combination (antiretroviral)
- Reverse transcriptase inhibitors
- Antiinfective agent stubs